Eloxx Pharmaceuticals, Inc. (ELOX) — Institutional Holders, Q2 2026

22 institutional investment managers reported a ELOX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $35.4M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

ELOX 13F holders ranked 1–22 of 22

Institutional investors reporting a position in Eloxx Pharmaceuticals, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Stonepine Capital Management#1 · 447,160 sh$6.2M—
Nantahala Capital Management#2 · 400,000 sh$5.6M—
EcoR1 Capital#3 · 400,000 sh$5.6M—
abrdn plc#4 · 400,000 sh$5.6M—
Samsara BioCapital#5 · 400,000 sh$5.6M—
Siren, L.L.C.#6 · 400,000 sh$5.6M—
VANGUARD CAPITAL MANAGEMENT#7 · 78,680 sh$1.1M—
VANGUARD FIDUCIARY#8 · 10,602 sh$147.2K—
SEVEN GRAND MANAGERS#9 · 10,000 sh$138.8K—
MORGAN STANLEY#10 · 1,544 sh$21.4K—
Vanguard Global Advisers#11 · 718 sh$10.0K—
UBS Group AG#12 · 637 sh$8.8K—
WELLS FARGO & COMPANY#13 · 126 sh$1.7K—
Pioneer Family Office#14 · 96 sh$1.3K—
ROYAL BANK OF CANADA#15 · 98 sh$1.0K—
Altshuler Shaham Ltd#16 · 25 sh$347.00—
BARCLAYS PLC#17 · 12 sh$167.00—
OLD POINT & FINANCIAL SERVICES N A#18 · 5 sh$69.00—
Activest Wealth Management#19 · 4 sh$56.00—
CITIGROUP#20 · 4 sh$56.00—
SBI Securities , Ltd.#21 · 2 sh$28.00—
Point Nemo Capital#22 · 1 sh$14.00—

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for the prior quarter without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.